We are alleviating the toxicity of the anticancer drug CPT-11 by modulating components of the GI microbiome. CPT-11 is essential in treating colorectal and pancreatic cancer, but dose-limiting toxicity severely reduces its efficacy. This toxicity is caused by a bacterial enzyme in enteric microbial symbiotes. The enzyme, beta glucuronidase, removes the inactivating glucuronic acid sugar from CPT-11's key metabolite, which reactivates the drug in the GI and produces epithelial cell death and acute diarrhea. We hypothesized that the selective, non-lethal inhibition of microbial beta glucuronidases would alleviate this side effect. This hypothesis tested true in proof-of-concept molecular-to-animal studies conducted in the previous project period. We will now advance the project in three crucial ways. First, we will characterize the range of active ?-glucuronidases present in the GI microbiome using structural biology and biochemistry. Second, we will create differentially optimized bacterial beta glucuronidase inhibitors via structural and chemical biology. Third, using deep-sequencing and metagenomics, we will unravel how this approach impacts the composition and activity of the GI microbiome. In summary, we seek to advance a novel paradigm - inhibiting specific microbial enzymes for therapeutic gain without harming the bacterial symbiotes essential for human health.

Public Health Relevance

We are alleviating the toxicity of the anticancer drug CPT-11 by modulating components of the GI microbiome. The results will reveal fundamental aspects of mammalian-microbial symbiosis and improve cancer chemotherapy.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Macromolecular Structure and Function A Study Section (MSFA)
Program Officer
Fu, Yali
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Schools of Arts and Sciences
Chapel Hill
United States
Zip Code
Pellock, Samuel J; Walton, William G; Biernat, Kristen A et al. (2018) Three structurally and functionally distinct ?-glucuronidases from the human gut microbe Bacteroides uniformis. J Biol Chem 293:18559-18573
Bhatt, Aadra P; Gunasekara, Dulan B; Speer, Jennifer et al. (2018) Nonsteroidal Anti-Inflammatory Drug-Induced Leaky Gut Modeled Using Polarized Monolayers of Primary Human Intestinal Epithelial Cells. ACS Infect Dis 4:46-52
Pellock, Samuel J; Creekmore, Benjamin C; Walton, William G et al. (2018) Gut Microbial ?-Glucuronidase Inhibition via Catalytic Cycle Interception. ACS Cent Sci 4:868-879
Yu, Ai-Ming; Ingelman-Sundberg, Magnus; Cherrington, Nathan J et al. (2017) Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO). Acta Pharm Sin B 7:241-248
Bhatt, Aadra P; Redinbo, Matthew R; Bultman, Scott J (2017) The role of the microbiome in cancer development and therapy. CA Cancer J Clin 67:326-344
Pollet, Rebecca M; D'Agostino, Emma H; Walton, William G et al. (2017) An Atlas of ?-Glucuronidases in the Human Intestinal Microbiome. Structure 25:967-977.e5
Pellock, Samuel J; Redinbo, Matthew R (2017) Glucuronides in the gut: Sugar-driven symbioses between microbe and host. J Biol Chem 292:8569-8576
Redinbo, Matthew R (2017) Microbial Molecules from the Multitudes within Us. Cell Metab 25:230-232
Ghodge, Swapnil V; Biernat, Kristen A; Bassett, Sarah Jane et al. (2016) Post-translational Claisen Condensation and Decarboxylation en Route to the Bicyclic Core of Pantocin A. J Am Chem Soc 138:5487-90
Wierdl, Monika; Tsurkan, Lyudmila; Hatfield, M Jason et al. (2016) Tumour-selective targeting of drug metabolizing enzymes to treat metastatic cancer. Br J Pharmacol 173:2811-8

Showing the most recent 10 out of 48 publications